InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,291.34
(
0.15%
)
US TECH 100
18,180.40
(
0.30%
)
Dow Jones
38,711.29
(
0.36%
)
Brent Oil
77.11
(
-1.32%
)
Bitcoin
70,558.99
(
2.55%
)
Post# of 252049
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 119762
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 156261

Friday, 02/15/2013 5:08:24 PM

Friday, February 15, 2013 5:08:24 PM

Post# of 252049
FDA grants priority review for GSK’s dolutegravir, a qD integrase inhibitor for HIV:

http://finance.yahoo.com/news/gsk-wins-priority-status-hiv-161639214.html

Dolutegravir may be as good as—or better than—GILD’s elvitegravir, the II constituent of Stribild. However, GSK plans to combine dolutegravir with GSK’s own Epzicom backbone (in place of Truvada), which is a big mistake, IMHO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up